New genome test could sharpen genetic insights for blood cancer patients

NCT ID NCT04986657

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 26 times

Summary

This study looks at whether a new whole genome test called ChromoSeq can give doctors more detailed genetic information for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) than current tests. Researchers will compare ChromoSeq results to standard genetic tests and ask doctors how useful the new information is. The goal is to see if ChromoSeq can help guide treatment decisions better. About 325 adults with suspected AML or MDS will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.